The use of medication in selective mutism: a systematic review.
Toronto, Canada. In Eur Child Adolesc Psychiatry, 09 Dec 2015
UNASSIGNED: Despite limited evidence, selective serotonin reuptake inhibitors (SSRIs) and monoamine oxidase inhibitors (MAOIs) are used to reduce symptoms of selective mutism (SM) in children unresponsive to psychosocial interventions.
The Use of Transdermal Therapeutic Systems in Psychiatric Care: A Primer on Patches.
Houston, United States. In Psychosomatics, Sep 2015
Such medications include cholinesterase inhibitors for dementia, methylphenidate (MPH) for attention-deficit hyperactivity disorder, monoamine oxidase inhibitors (MAOIs) for depression, dopamine agonists for Parkinson disease and restless leg syndrome, and clonidine for attention-deficit hyperactivity disorder and impulse-control disorders.
[Gap junctions: A new therapeutic target in major depressive disorder?]
Poitiers, France. In Rev Neurol (paris), Sep 2015
The treatments of this disease with tricyclic antidepressants and monoamine oxidase inhibitors are poorly tolerated and those that selectively target serotonin and norepinephrine re-uptake are not effective in all patients, showing the need to find new therapeutic targets.
Inhibition and oxygen activation in copper amine oxidases.
Bozeman, United States. In Acc Chem Res, Jun 2015
Inhibition of these enzymes by antifungal or antiprotozoal agents, as well as classic monoamine oxidase (MAO) inhibitors, may contribute to the adverse side effects associated with drug treatment.
[Current state and potential of pharmacogenetic studies in the treatment of depression].
In Zh Nevrol Psikhiatr Im S S Korsakova, Dec 2014
The following sections of the review are devoted to the above issues: adrenoreceptors, serotonin transporter protein, dopamine transporter protein, monoamine oxidase A, catechol-O-methyltransferase, brain-derived neurotrophic factor, the hypothalamic-pituitary-adrenal system, G-proteins, the glutamatergic system.
Pharmacological treatment of Parkinson disease: a review.
Hamilton, Canada. In Jama, May 2014
RESULTS: Although levodopa is the most effective medication available for treating the motor symptoms of Parkinson disease, in certain instances (eg, mild symptoms, tremor as the only or most prominent symptom, aged <60 years) other medications (eg, monoamine oxidase type B inhibitors [MAOBIs], amantadine, anticholinergics, β-blockers, or dopamine agonists) may be initiated first to avoid levodopa-related motor complications.